dr Belinda de Villiers
dr Belinda de Villiers
dr Belinda de Villiers
Belinda currently holds an AQIRF fellowship for her work contributing towards a solution for the current SARS-CoV-2 pandemic. She also holds an ACH2 grant to develop a diagnostic tool for HTLV-1 and lymphocytosis, aimed at patients in the remote Australian outback.
dr JUN ZHANG
dr Belinda de Villiers
dr Belinda de Villiers
Dr. Jun Zhang is a senior lecturer and ARC Future Fellow (2025-29) at the School of Engineering and Built Environment, Griffith University. He received his PhD degree at the University of Wollongong in Dec 2015. He has ttracted 15 grants, with the total research income of AUD$2.6M, where AUD$1.8M as Lead CI or Fellowship, including ARC Fu
Dr. Jun Zhang is a senior lecturer and ARC Future Fellow (2025-29) at the School of Engineering and Built Environment, Griffith University. He received his PhD degree at the University of Wollongong in Dec 2015. He has ttracted 15 grants, with the total research income of AUD$2.6M, where AUD$1.8M as Lead CI or Fellowship, including ARC Future (2024), DECRA (2021) and German Humboldt (2020) fellowship. His research is dedicated to developing and deploying advanced micro and nanotechnology (e.g., microfluidics and Lab on a Chip) to improve and facilitate disease diagnosis and therapeutics. Dr Zhang has published ~90 journal articles in international journals such as Lab On A Chip, Analytical Chemistry, Sensors&Actuators B, SMALL, Nano Letter, Scientific Reports, and Advanced Functional Materials etc and three book chapters. He was a visiting scholar at the University of California, Los Angeles (UCLA) (2014), Griffith University (2014), and Harvard University (2019), a research scientist at the University of Sydney (2015), and a research fellow at the University of Wollongong (2015-2016), an associate professor at the Nanjing University of Science and Technology (NUST, 2016-2018). He received the Australian Nanotechnology Network (ANN) Overseas Travel Fellowship (2019), Griffith Science Pro Vice Chancellor's Research Excellence Award- Early Career Research (2020) and -Excellence of a research group (2020). Dr Zhang is a member of ACS, and has reviewed >200 papers for >60 international journals: (e.g., Lab Chip, Nat. Commun., Anal. Chem.,SMALL, Microsyst. Nanoeng., PRL, Microfluid. Nanofluid., Sci. Rep., ACS Appl. Mater. Interfaces, IEEE Trans. Mechatron., IEEE Trans. Biomed. Circuits Syst., Appl Phys Lett etc.). He is an Associate Editor for Microsystem Technologies (Springer, 2023-), Micro & Nano Letters (IET, 2020-) and Frontiers in Medical Technology | Diagnostic and Therapeutic Devices (2021-) and a Topic Board member of the Journal of Fluids (2020-). He has been on the Stanford list of the World's Top 2% scientists since 2020.
Dr Andrew Rayfield
dr Belinda de Villiers
Dr Andrew Rayfield
Dr Andrew Rayfield is a Research Fellow and Research Commercialisation Manager for the Clem Jones Centre for Neurobiology and Stem Cell Research (CJCNSCR). Andrew spends his time at the CJCNSCR labs in Brisbane and on the Gold Coast. Andrew is a molecular and cellular neuroscientist by training with six years’ experience in industry and n
Dr Andrew Rayfield is a Research Fellow and Research Commercialisation Manager for the Clem Jones Centre for Neurobiology and Stem Cell Research (CJCNSCR). Andrew spends his time at the CJCNSCR labs in Brisbane and on the Gold Coast. Andrew is a molecular and cellular neuroscientist by training with six years’ experience in industry and nearly twenty years experience in academia. Andrew's role as Research Commercialisation Manager for the Centre is to develop and translate the Centre's three main areas of preclinical research (developing a therapy for spinal cord injury; developing a therapy for peripheral nerve injury; and identifying the causes of, and developing diagnostics for neurodegeneration) into clinical products. As part of the Spinal Injury Project, Andrew is working closely with members of the Centre and external stakeholders to propel the Centre's pre-clinical research towards a Phase I cell and rehabilitation clinical trial, set to commence in 2024 (GUSIP03). The Centre's goal is to complete the clinical phases of development and produce a therapy product for spinal cord injury, available to all around the world. Andrew has previously managed the Centre as Research Manager (2017-2023) where he managed HDR students, budgets, publication output, grants and funding, ethics, clinical trial development, quality control, marketing and design, external stakeholder management, and social media. Andrew previously helped run the GUSIP01 and the GUSIP02 feasibility clinical trials where Griffith was the sponsor. The aim of these trials were to test the feasibility of an intensive exercise-based rehabilitation for spinal cord injury patients. In addition to management roles in the Centre, Andrew has a keen interest in the cellular biology of glia, has developed skills in qualitative research to help assess the barriers and facilitators of intensive exercise rehabilitation for spinal cord injury patients, and has an interest in implementation science. Andrew's main focus, however is in research commercialisation and entrepreneurship. Since 2020 Andrew has been a member of the Griffith Pride Committee and commenced as Co-Chair in 2022 and as Chair in 2024. Andrew believes it is important to be true to yourself in all aspects of your life, including bringing your true self to the work place. Something a lot of people in the world still cannot or are unable to do.
dr YUN SHI (Chair)
dr YUN SHI (Chair)
dr YUN SHI (Chair)
Dr. Yun Shi is an ARC DECRA Fellow and an NHMRC Investigator (Emerging Leadership) with multiple high-impact publications in prestigious journals such as Science, Molecular Cell, and Neuron. He routinely integrates computational, biophysical, and biochemical methods to investigate the interactions between proteins and their ligands at the
Dr. Yun Shi is an ARC DECRA Fellow and an NHMRC Investigator (Emerging Leadership) with multiple high-impact publications in prestigious journals such as Science, Molecular Cell, and Neuron. He routinely integrates computational, biophysical, and biochemical methods to investigate the interactions between proteins and their ligands at the molecular level. Dr. Shi joined Griffith University after obtaining a PhD in Chemistry from Simon Fraser University (2015). With a Griffith University Postdoctoral Fellowship (2016), he established a fragment-based drug discovery platform using nuclear magnetic resonance (NMR) spectroscopy as the primary technique. This platform has generated and optimized numerous hits for a variety of drug discovery programs. Dr. Shi's current research focuses on understanding the molecular mechanisms for the function and inhibition of enzymes involved in nicotinamide adenine dinucleotide (NAD+) metabolism. These include NAD+ glycohydrolases and NAD+ synthases that are promising therapeutic targets against neurodegeneration and infectious diseases.
Dr MIAOMIAO LIU
dr YUN SHI (Chair)
dr YUN SHI (Chair)
Dr Liu received her double PhD degree (2017) in natural product chemistry from Griffith University and the University of Chinese Academy of Sciences under the supervision of professors Ronald J Quinn and Lixin Zhang. She is currently a NHMRC fellow in the Griffith Institute for Drug Discovery (GRIDD). Throughout her early academic career,
Dr Liu received her double PhD degree (2017) in natural product chemistry from Griffith University and the University of Chinese Academy of Sciences under the supervision of professors Ronald J Quinn and Lixin Zhang. She is currently a NHMRC fellow in the Griffith Institute for Drug Discovery (GRIDD). Throughout her early academic career, she has studied natural product discovery and protein-ligand interactions using native mass spectrometry (MS) and could be considered internationally as one of the experts of this specialised research area. Dr Liu has a career total of 44 research outputs, consisting of 41 peer-reviewed publications (12 as first/senior author), 1 book chapter and 2 patent applications in the field of native MS, NP chemistry and microbial metabolomics.
DR MEGHA MOHAN
dr YUN SHI (Chair)
DR MEGHA MOHAN
Dr. Megha Mohan is a Research Fellow at the Clem Jones Centre for Neurobiology and Stem Cell Research. She completed her PhD in cell and molecular biology at Griffith University in 2017. Her current role involves working on characterization of olfactory derived mucosal cells to use them as a cell therapy for spinal cord injury. She is
Dr. Megha Mohan is a Research Fellow at the Clem Jones Centre for Neurobiology and Stem Cell Research. She completed her PhD in cell and molecular biology at Griffith University in 2017. Her current role involves working on characterization of olfactory derived mucosal cells to use them as a cell therapy for spinal cord injury. She is part of a large team that aims to translate a cell therapy product to the clinic to aid in the improvement of health for spinal cord injury patients.
Dr Xiaying Qi
Dr Biswa Prasanna Mishra
DR MEGHA MOHAN
Dr Xiaying Qi is a postdoctoral fellow from the Institute for Biomedicine and Glycomics, the Australian Centre for Health and Precision Technology and the School of Medicine and Dentistry.
Dr Biswa Prasanna Mishra
Dr Biswa Prasanna Mishra
Dr Biswa Prasanna Mishra
Dr Biswa Prasanna Mishra is a Postdoctoral Research Fellow at the Institute for Biomedicine and Glycomics, where he uses structural biology methods (X-ray Crystallography, NMR and Cryo-EM) combined with chemistry-based approaches to characterise proteins and protein complexes to better understand signalling mechanisms in biological proces
Dr Biswa Prasanna Mishra is a Postdoctoral Research Fellow at the Institute for Biomedicine and Glycomics, where he uses structural biology methods (X-ray Crystallography, NMR and Cryo-EM) combined with chemistry-based approaches to characterise proteins and protein complexes to better understand signalling mechanisms in biological processes, including human disease processes and bacterial defence systems. He obtained his PhD in molecular and structural biology from the University of Queensland.
dr Haotian Cha
Dr Biswa Prasanna Mishra
Dr Biswa Prasanna Mishra
Dr Haotian Cha is currently a Research Fellow at the Queensland Micro Nanotechnology Centre (QMNC), Griffith University. He received his bachelor’s degree in mechanical engineering from Nanjing University of Science and Technology (NUST) and a master’s degree in mechanical engineering from the University of New South Wales (UNSW). Dr Haot
Dr Haotian Cha is currently a Research Fellow at the Queensland Micro Nanotechnology Centre (QMNC), Griffith University. He received his bachelor’s degree in mechanical engineering from Nanjing University of Science and Technology (NUST) and a master’s degree in mechanical engineering from the University of New South Wales (UNSW). Dr Haotian Cha has published 16 journal articles in international journals such as Lab On A Chip, Cyborg and Bionic Systems, Small, Chemical Engineering Science, Nanoscale, etc.
DR ju jin
DR JAMILA IQBAL
DR JAMILA IQBAL
Dr. Ju Jin is a Research Fellow at the Clem Jones Centre for Neurobiology and Stem Cell Research.
DR JAMILA IQBAL
DR JAMILA IQBAL
DR JAMILA IQBAL
Dr Jamila Iqbal is working as a Postdoctoral Research Fellow at Griffith Institute for Drug Discovery (GRIDD), Griffith University. She received her doctoral degree from Griffith University, where her research focussed on using small molecules probes to elucidate the mechanisms underlying Parkinson's disease. Currently, her research cent
Dr Jamila Iqbal is working as a Postdoctoral Research Fellow at Griffith Institute for Drug Discovery (GRIDD), Griffith University. She received her doctoral degree from Griffith University, where her research focussed on using small molecules probes to elucidate the mechanisms underlying Parkinson's disease. Currently, her research centers on using olfactory stem cells from patients with different neurological conditions to uncover biomarkers and screening potential treatments to counteract disease progression. She's developing image-based assays to identify disease-related traits in patient cells, aiming to establish biomarkers for drug screening. Her expertise extends to big data analysis, high content imaging assays and the application of artificial intelligence, reflecting her profound interest in advancing these fields.
DR yuqing mu
DR JAMILA IQBAL
MS Jiaying liu
Dr Yuqing Mu is a postdoctoral fellow from the Australian Centre for Health and Precision Technology and School of Medicine and Dentistry.
MS Jiaying liu
MR patrick tang
MS Jiaying liu
Ms Jiaying Liu is a PhD student from the Australian Centre for Health and Precision Technology and School of Medicine and Dentistry.
MR patrick tang
MR patrick tang
MR patrick tang
Mr Patrick Tang is a PhD student from the School of Pharmacy and Medical Sciences.
THANK YOU TO OUR GRIFFITH UNIVERSITY SPONSORS
Griffith Science
Menzies Health Institute Queensland
Griffith Science
Griffith Science facilitates broad-based research within a global learning and teaching environment. Find out more here.
Griffith Health
Menzies Health Institute Queensland
Griffith Science
Griffith Health is highly ranked worldwide as a provider of health education and research. Find out more here.
Menzies Health Institute Queensland
Menzies Health Institute Queensland
Menzies Health Institute Queensland
The Menzies Health Institute Queensland (MHIQ): Translating innovative health research into better health outcomes. Find out more here.
Institute for Glycomics
Queensland Micro Nanotechnology Centre
Menzies Health Institute Queensland
The Institute for Glycomics' research primarily targets prevention and cures for infectious diseases, cancer and neurodegenerative disorders, with a focus on translational research. Find out more here.
Griffith Institute for Drug Discovery
Queensland Micro Nanotechnology Centre
Queensland Micro Nanotechnology Centre
Griffith Institute for Drug Discovery (GRIDD) is a world-class research facility, offering unique resources and drawing on a global network of partners to target the world’s most devastating diseases. Find out more here.
Queensland Micro Nanotechnology Centre
Queensland Micro Nanotechnology Centre
Queensland Micro Nanotechnology Centre
Queensland Micro Nanotechnology Centre (QMNC) has core capabilities in microtechnology, nanotechnology and micro/nanosystems. Find out more here.